Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BDKRB1 | P46663 | 1/20 | 0.48 |
| ▸ | HTR2A | P28223 | 2/20 | 0.41 |
| ▸ | HTR2C | P28335 | 2/20 | 0.41 |
| ▸ | HTR2B | P41595 | 2/20 | 0.41 |
| ▸ | F10 | P00742 | 15/20 | 0.40 |
| ▸ | HRH2 | P25021 | 1/20 | 0.37 |
| ▸ | HRH1 | P35367 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
| ▸ | F2 | P00734 | 2/20 | 0.34 |
| ▸ | ELANE | P08246 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4712314 | 0.92 | BDKRB1 (0.49) | BDKRB1HTR2AHTR2CHTR2BF10 | |
| SCHEMBL4716630 | 0.88 | HTR2A (0.41) | BDKRB1HTR2AHTR2CHTR2BHRH3 | |
| SCHEMBL4716498 | 0.87 | AKT1 (0.41) | BDKRB1HTR2AHTR2CHTR2B | |
| SCHEMBL4712302 | 0.86 | BDKRB1 (0.51) | BDKRB1HTR2AHTR2CHTR2BF10 | |
| SCHEMBL5630710 | 0.86 | BDKRB1 (0.48) | BDKRB1HTR2AHTR2CHTR2BF10 | |
| SCHEMBL4711860 | 0.85 | BDKRB1 (0.51) | BDKRB1HTR2AHTR2CHTR2BF10 | |
| SCHEMBL5628644 | 0.84 | GPR119 (0.40) | BDKRB1HTR2AHTR2CHTR2B | |
| SCHEMBL4717629 | 0.80 | BDKRB1 (0.49) | BDKRB1HTR2AHTR2CHTR2BF10 | |
| SCHEMBL4714752 | 0.79 | HTR2A (0.40) | BDKRB1HTR2AHTR2CHTR2B | |
| SCHEMBL4712921 | 0.78 | BDKRB1 (0.52) | BDKRB1HTR2AHTR2CHTR2BHRH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070032475-A1 | Novel compounds useful for bradykinin B1 receptor antagonism | ELAN PHARMACEUTICALS, INC. | 2007-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032475-A1 | Novel compounds useful for bradykinin B1 receptor antagonism | BDKRB1, BDKRB2, NPBWR1 | BDKRB1 1/4885HTR2A 742/4885HTR2C 1740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.